CADILA HEALTHCARE LTD. - 532321 - Cadila Healthcare Ltd reply to clarification sought by the exchange
The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news article appearing on abplive.com April 07, 2020 titled "COVID 19 - Cadila Healthcare claims to make coronavirus medicine".Cadila Healthcare Ltd response is enclosed.
Cadila share price surges 15% on USFDA approval for Perphenazine tablets
The drug is for the treatment of schizophrenia and controlling severe nausea and vomiting in adults. CADILA HEALTHCARE LTD. - 532321 - Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing on abplive.com April 07, 2020 titled "COVID 19 - Cadila Healthcare claims to make coronavirus medicine". The reply is awaited. CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA for Perphenazine Tablets USP Two coronavirus vaccine candidates enter human trials, 60 in pre-clinical stage: WHO
As reported earlier, India's Zydus Cadila, Serum Institute and Bharat Biotech are among the global firms working on COVID-19 vaccine Zydus Cadila gets final nod from USFDA to market generic seizures drug
The group now has 283 approvals and has so far filed over 386 abbreviated new drug applications CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Lamotrigine Extended-Release Tablets
Cadila, Ipca gain 4-9% after US allows emergency use of antimalarial drugs for COVID-19
Cadila Healthcare and Ipca Labs are prominent manufacturers of hydroxychloroquine and chloroquine in India. Both are antimalarial drugs. 
Zydus Cadila gets tentative nod from USFDA for Parkinson's treatment capsule
The approval by the US Food and Drug Administration is for Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg, Cadila Healthcare said in a regulatory filing.